- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
- XOMA Corporation Announces Closing of Tender Offer
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- XOMA to Present at Upcoming Investor Conferences in March
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
More ▼
Key statistics
On Wednesday, XOMA Corp (XOMAP:NMQ) closed at 25.10, -3.39% below its 52-week high of 25.98, set on Dec 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.10 |
---|---|
High | 25.10 |
Low | 25.10 |
Bid | 25.02 |
Offer | 25.52 |
Previous close | 25.10 |
Average volume | 1.60k |
---|---|
Shares outstanding | 11.64m |
Free float | 11.58m |
P/E (TTM) | -- |
Market cap | 293.29m USD |
EPS (TTM) | -3.92 USD |
Annual div (ADY) | 2.16 USD |
---|---|
Annual div yield (ADY) | 8.59% |
Div ex-date | Apr 02 2024 |
Div pay-date | Apr 15 2024 |
Data delayed at least 15 minutes, as of May 22 2024 19:08 BST.
More ▼